Tech Company Financing Transactions
TScan Therapeutics Funding Round
On 1/10/2020, TScan Therapeutics received $35 million in Series B funding from 6 Dimensions Capital, Astellas Venture Capital and Bessemer Venture Partners.
Transaction Overview
Company Name
Announced On
1/10/2020
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to expand its development efforts.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
830 Winter St.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
TScan Therapeutics is an experienced group of scientists, development specialists, and other leaders driving a cutting edge platform. TScan Therapeutics is an owner and operator of a biotechnology company intended to develop immunotherapy treatments for cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Southwell
Chief Scientific Officer
Gavin MacBeath
VP - Bus. Development
Henry Rath
VP - Finance
Shane Maltbie
VP - Human Resources
Ann Hargraves
Browse more venture capital transactions:
Prev: 1/10/2020: Progentec venture capital transaction
Next: 1/10/2020: Element Biosciences venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs